The Manufacturers Life Insurance Company Takes $487.31 Million Position in Abbott Laboratories $ABT

The Manufacturers Life Insurance Company purchased a new position in shares of Abbott Laboratories (NYSE:ABT) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 5,370,397 shares of the healthcare product maker’s stock, valued at approximately $487,310,000.

Other large investors have also recently added to or reduced their stakes in the company. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories during the fourth quarter worth $25,000. Cornerstone Financial Management LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories during the 4th quarter worth $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories during the 4th quarter worth $26,000. Finally, Abound Financial LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth about $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Citigroup upped their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target on the stock. TD Cowen upped their price objective on shares of Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. JPMorgan Chase & Co. increased their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Finally, Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price for the company in a report on Thursday, August 13th. Three research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories Stock Performance

NYSE ABT opened at $108.86 on Wednesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The company has a market cap of $188.37 billion, a P/E ratio of 35.23, a P/E/G ratio of 2.05 and a beta of 0.59. The stock has a 50-day moving average of $103.43 and a two-hundred day moving average of $100.09. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter in the prior year, the company earned $1.26 earnings per share. The business’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio is 81.55%.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New infant formula expands Abbott’s nutrition portfolio. Abbott launched Similac 360 Total Care Made With Whole Milk, described as the first commercially sterile, ready-to-feed liquid whole-milk infant formula available in the U.S. The product targets growing parental interest in whole-milk formulas while offering convenience at a price similar to Similac’s powdered formula. Wider distribution and consumer adoption could provide incremental growth for Abbott’s Nutrition segment. Abbott launches whole-milk liquid infant formula
• Positive Sentiment: Analysts remain optimistic despite relative underperformance. Coverage notes that ABT has lagged the broader healthcare sector over the past year, but Wall Street analysts continue to express confidence in the company’s outlook. Recent earnings also showed revenue growth, an earnings-per-share beat and reaffirmed 2026 guidance, supporting the bullish view. Abbott stock and healthcare-sector performance
• Neutral Sentiment: Abbott is positioning the launch around changing consumer and policy preferences. The whole-milk formula introduction aligns with interest in “Make America Healthy Again” themes, but the financial impact will depend on demand, pricing and market share gains. Abbott and the Make America Healthy Again movement
• Negative Sentiment: Formula-related advertising scrutiny remains a risk. In a challenge brought by Abbott, the National Advertising Division supported certain Kendamil whole-milk claims but recommended that other nutritional, ingredient and heritage claims be modified or discontinued. The decision is not a direct finding against Abbott, but it highlights competitive scrutiny in the infant-formula market. NAD decision on Kendamil infant formula claims

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.